94 related articles for article (PubMed ID: 16566978)
21. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
Zhang G; Cao Y; Xu Y; See WA
Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119
[TBL] [Abstract][Full Text] [Related]
22. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
23. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation.
Adshead JM; Ogden CW; Penny MA; Stuart ET; Kessling AM
BJU Int; 1999 Jun; 83(9):1039-44. PubMed ID: 10368252
[TBL] [Abstract][Full Text] [Related]
24. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
[TBL] [Abstract][Full Text] [Related]
25. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
26. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
27. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
[TBL] [Abstract][Full Text] [Related]
29. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
30. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
[TBL] [Abstract][Full Text] [Related]
31. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
Tsui KH; Juang HH; Lee TH; Chang PL; Chen CL; Yung BY
Acta Pharmacol Sin; 2008 Mar; 29(3):364-70. PubMed ID: 18298902
[TBL] [Abstract][Full Text] [Related]
32. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
[TBL] [Abstract][Full Text] [Related]
34. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
35. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
36. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
38. Bradeion (SEPT4) as a urinary marker of transitional cell bladder cancer: a real-time polymerase chain reaction study of gene expression.
Bongiovanni L; Pirozzi F; Guidi F; Orsini M; Chiurazzi P; Bassi PF; Racioppi M
J Urol; 2012 Jun; 187(6):2223-7. PubMed ID: 22503047
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
40. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]